

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 27 June 2022 (the “**Prospectus**”) issued by Rainmed Medical Limited (潤邁德醫療有限公司) (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional buyers (as defined in Rule 144A under the U.S. Securities Act) pursuant to Rule 144A or another available exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

RainMed

Rainmed Medical Limited

潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2297)

**PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION
STABILIZING ACTIONS
AND END OF STABILIZATION PERIOD**

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Sole Global Coordinator on behalf of the International Underwriters on Saturday, 30 July 2022 in respect of an aggregate of 451,000 Shares, representing approximately 1.93% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Opera Rose Limited part of the 3,021,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocations under the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK\$6.24 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on Saturday, 30 July 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Further information in relation to the stabilization actions undertaken by Huatai Financial Holdings (Hong Kong) Limited, the Stabilizing Manager, or any person acting for it, during the stabilization period, is set out in this announcement.

PUBLIC FLOAT

Immediately after the end of the stabilization period and the completion of the partial exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rules 8.08(1)(a) and 18A.07 of the Listing Rules.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Sole Global Coordinator on behalf of the International Underwriters on Saturday, 30 July 2022 in respect of an aggregate of 451,000 Shares (the “**Over-allotment Shares**”), representing approximately 1.93% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Opera Rose Limited part of the 3,021,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocations under the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK\$6.24 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering.

APPROVAL FOR LISTING

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on Wednesday, 3 August 2022 (Hong Kong time).

SHAREHOLDING STRUCTURE OF THE COMPANY UPON COMPLETION OF THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after completion of the partial exercise of the Over-allotment Option is as follows (assuming that no Shares are issued under the Pre-IPO Share Option Scheme):

Shareholders	Immediately before completion of the partial exercise of the Over-allotment Option		Immediately after completion of the partial exercise of the Over-allotment Option	
	Number of issued Shares	Approximate % of the Company's issued share capital	Number of issued Shares	Approximate % of the Company's issued share capital
Opera Rose Limited ⁽¹⁾	214,749,000	18.40	214,749,000	18.39
Vermilion Bird Limited ⁽²⁾	159,934,000	13.70	159,934,000	13.70
Tongxiang Haoqian and Tongchuang Guosheng ⁽³⁾	129,606,000	11.10	129,606,000	11.10
Ping An Investment and Haihui Quanli ⁽⁴⁾	120,000,000	10.28	120,000,000	10.28
Other connected persons ⁽⁵⁾	40,721,000	3.49	40,721,000	3.49
Public Shareholders	502,338,000	43.03	502,789,000	43.05
Total	1,167,348,000	100.00	1,167,799,000	100.00

Notes:

- (1) Opera Rose Limited is owned as to 99.9% by Dawning Sky Limited and 0.1% by Mr. Huo (through Rainmed01 Limited), respectively. Dawning Sky Limited is wholly owned by The Core Trust Company Limited, being the trustee of the Opera Rose Trust which is a discretionary trust established by Mr. Huo as the settlor and beneficiary.
- (2) Vermilion Bird Limited is owned as to 99.9% by Glowing Fame Limited and 0.1% by Dr. Huo Yunlong (through Hyljrkcyn888 Limited), respectively. Glowing Fame Limited is wholly owned by the Core Trust, being the trustee of the Vermilion Bird Trust which is a discretionary trust established by Dr. Huo Yunlong as the settlor and beneficiary.
- (3) Tongxiang Haoqian is a limited partnership established in the PRC. The general partner of Tongxiang Haoqian is Xinyu Tongchuang Investment Management Co., Ltd.* (新余同創精選投資管理有限公司) which is wholly-owned by Shenzhen Cowin Asset Management Co., Ltd.* (深圳同創偉業資產管理股份有限公司), a company listed on National Equities Exchange and Quotations (832793.NEEQ). Tongchuang Guosheng is a limited partnership established in the PRC. The general partner of Tongchuang Guosheng is Shenzhen Cowin Jinxiu Asset Management Co., Ltd.* (深圳同創錦繡資產管理有限公司) which is also wholly-owned by Cowin (832793.NEEQ).
- (4) Each of Ping An Investment and Haihui Quanli is a limited partnership established in the PRC. The general partners of Ping An Investment and Haihui Quanli are Shenzhen Ping An Properties Investment Co., Ltd.* (深圳市平安置業投資有限公司) and Ping An Capital Co., Ltd.* (平安資本有限責任公司), respectively, both of whom are ultimately owned by Ping An Insurance (Group) Company of China, Ltd. (中國平安保險(集團)股份有限公司) (02318.HK and 601318.SH).
- (5) Such equity interest of the Company is held by (a) Mingze, which is wholly owned by Mr. Lyu Yonghui, an executive Director and joint chief executive officer of the Company; (b) ANC HK, which is wholly owned by Mr. Zhang Liang, an executive Director, chief financial officer and joint company secretary of the Company; (c) ASHG HK, which is wholly owned by Ms. Gu Yang, an executive Director and a vice president of the Company.

USE OF PROCEEDS

The Company will receive additional net proceeds of approximately HK\$2.8 million (after deducting the underwriting commissions and other estimated expenses payable by the Company in connection with the partial exercise of the Over-allotment Option) for the 451,000 Shares to be issued and allotted following the partial exercise of the Over-allotment Option. The additional net proceeds will be used by the Company for the purposes and in the proportions as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Saturday, 30 July 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilizing actions undertaken by Huatai Financial Holdings (Hong Kong) Limited, the Stabilizing Manager, or any person acting for it, during the stabilization period are set out below:

- (i) over-allocations of an aggregate of 3,021,000 Shares under the International Offering, representing approximately 12.94% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (ii) the borrowing of an aggregate of 3,021,000 Shares from Opera Rose Limited pursuant to the Stock Borrowing Agreement to cover over-allocation under the International Offering;
- (iii) successive purchases of an aggregate of 2,570,000 Shares in the price range of HK\$4.85 to HK\$6.01 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) on the market during the stabilization period, representing approximately 11% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The last purchase made by the Stabilizing Manager or any person acting for it, on the market during the course of the stabilization period was on Thursday, 28 July 2022 at the price of HK\$5.12 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%);

- (iv) the partial exercise of the Over-allotment Option by the Sole Global Coordinator on behalf of the International Underwriters on Saturday, 30 July 2022 in respect of an aggregate of 451,000 Shares, representing approximately 1.93% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at HK\$6.24 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering, to facilitate the return to Opera Rose Limited of the remaining part of the 3,021,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocations under the International Offering;
- (v) there had been no sale of any Shares on the market for the purpose of price stabilization by the Stabilization Manager during the stabilization period; and
- (vi) the portion of the Over-allotment Option which has not been exercised by the Sole Global Coordinator on behalf of the International Underwriters lapsed on Saturday, 30 July 2022.

PUBLIC FLOAT

Immediately after the end of the stabilization period and the completion of the partial exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rules 8.08(1)(a) and 18A.07 of the Listing Rules.

By order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, 1 August 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Huo Yunfei, Mr. Lyu Yonghui, Mr. Zhang Liang and Ms. Gu Yang as executive Directors; Mr. Wang Lin and Mr. Heng Lei as non-executive Directors; Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Lau Tsz Ho Tony as the independent non-executive Directors.

* *For identification purpose only*